Every year in the United States, roughly 54,000 people are diagnosed with cancers of the oral cavity and throat. Most Americans have never heard of oropharyngeal cancer — cancer of the back of the throat, the base of the tongue, and the tonsils. Yet it is one of the fastest-rising malignancies in the country, driven by a virus that most sexually active adults have been exposed to, frequently causes no symptoms until the cancer is already advanced, and disproportionately strikes a group that has historically been told they are not at risk: men in their 50s and 60s who have never smoked. A convergence of landmark epidemiology research, a paradigm-shifting clinical trial published in The Lancet, and a vaccine that may already be preventing new cases paints a picture that every American adult deserves to understand.
A Cancer Quietly Climbing the Charts
For most of the twentieth century, cancers of the head and neck were diseases of heavy smokers and heavy drinkers. The pattern made intuitive sense: decades of exposure to tobacco carcinogens and alcohol wreaked havoc on the mucous membranes lining the mouth and throat, eventually triggering malignant transformation. Rates were declining in the 1990s and early 2000s as smoking rates fell — until they weren’t.
Beginning in the 1980s and accelerating through the 1990s, a new subtype of throat cancer began rising steadily, against the broader downward trend. Rates of cancer at one specific anatomical site — the oropharynx, which includes the tonsils and the base of the tongue — were climbing, not falling. And the patients getting it looked nothing like the traditional profile: many were non-smokers, non-drinkers, otherwise healthy, and predominantly male.
By the time researchers fully characterized what was happening, oropharyngeal squamous cell carcinoma (OPSCC) had become one of the few cancers in the United States with a significantly increasing incidence. The NCI’s SEER database shows that while cancers of the oral cavity have remained relatively flat, oropharyngeal cancers driven by a specific cause rose by roughly 225% between 1988 and 2004 alone. And projections suggest the incidence will continue increasing through the 2030s, a delayed consequence of an exposure that happened decades ago.
The Unexpected HPV Connection
The explanation came from a meticulous epidemiological study published in the Journal of Clinical Oncology in 2011. Researchers led by Anil Chaturvedi at the National Cancer Institute analyzed tumor samples from oropharyngeal cancer cases registered in the SEER database between 1984 and 2004. Using molecular testing, they found that the proportion of oropharyngeal tumors testing positive for Human Papillomavirus (HPV) — specifically the HPV16 strain — had risen from 16% in the late 1980s to 72% by the mid-2000s.
The implication was stark: a sexually transmitted virus was responsible for the majority of oropharyngeal cancers, and that proportion was only growing. In the United States today, HPV is estimated to cause approximately 70% of all oropharyngeal cancers.
Most people associate HPV with genital infections and cervical cancer. The link is well established and has driven decades of screening (Pap smears) and, more recently, vaccination. But HPV is also transmitted orally, and when it establishes a persistent infection in the tissues at the back of the throat, it can trigger the same malignant process it causes in the cervix — just in a different location. The biological mechanism is identical: HPV16 produces proteins (E6 and E7) that disable the cell’s two key tumor suppressor genes, p53 and Rb, essentially switching off the brakes on uncontrolled cell division.
Who Gets This Cancer — and Why
The epidemiological profile of HPV-positive oropharyngeal cancer is strikingly specific, and it is one of the features that most surprises patients and their families when they receive a diagnosis.
The disease predominantly affects white men between 45 and 70. The incidence among men is three to four times higher than among women. It is more common in college-educated, non-smoking populations than in lower socioeconomic groups — the inverse of the pattern for most other cancers. And its primary risk factor is the lifetime number of oral sex partners, not smoking or alcohol.
The reason for the male predominance is not fully understood. HPV infection of the throat is common in both sexes; studies suggest roughly 7–10% of American adults currently carry an oral HPV infection at any given time. But men are less likely to clear the infection naturally, and more likely to develop a persistent oral HPV infection that eventually triggers cancer. Why the immune system behaves differently in men is an active area of research, with hormonal, microbiome, and mucosal immunity differences all under investigation.
The age of diagnosis — typically the 50s to early 60s — reflects the long latency between initial HPV exposure (usually in the teens and twenties during a period of sexual activity) and malignant transformation. HPV can persist silently in throat tissue for decades before causing cancer. A person exposed to HPV orally at 22 might not develop oropharyngeal cancer until age 58 or 62.
This latency period also explains why this cancer is concentrated in the generation born roughly between 1945 and 1965 — a cohort that came of age before HPV was understood as a health risk, before the vaccine existed, and during a period of significant changes in sexual behavior. They are now at the peak of their cancer-risk window.
A Paradox: A Worse Cause, a Better Prognosis
One of the most striking features of HPV-positive oropharyngeal cancer — and one of the most important things for newly diagnosed patients to understand — is that despite its rising incidence and often late-stage diagnosis, it is dramatically more responsive to treatment than HPV-negative throat cancer.
The five-year survival rate for HPV-positive oropharyngeal cancer is approximately 80–90%, even at stage III. For HPV-negative oropharyngeal cancer — driven by tobacco and alcohol, and declining in incidence — the five-year survival rate is closer to 40–50% at the same stage. This is not a marginal difference; it is a profound biological distinction between two cancers that happen to occur in the same anatomical location.
The reason lies in how HPV-positive tumors respond to the immune system and to treatment. Because these tumors are driven by viral antigens, the immune system is already partially engaged with them — they are perceived as more “foreign” than tumors arising purely from tobacco damage. They also tend to respond more completely to radiation and chemotherapy, for reasons that are still being fully elucidated. The implication is that many patients diagnosed with HPV-positive throat cancer, even at relatively advanced local stages, are genuinely curable.
This biological distinction has driven one of the most important questions in head and neck oncology: since HPV-positive patients do so well, can we give them less treatment — with fewer long-term side effects from radiation — without sacrificing outcomes? De-escalation trials testing reduced-dose radiotherapy and less intensive chemotherapy regimens are actively being studied for this exact reason. But the standard of care has simultaneously been transformed by another development: immunotherapy.
The Immunotherapy Breakthrough: KEYNOTE-048
For patients whose oropharyngeal cancer recurs after initial treatment — or who are diagnosed with metastatic disease that has spread beyond the head and neck region — the treatment landscape was, until recently, bleak. The standard first-line regimen for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) had been a combination called EXTREME (cetuximab with platinum-based chemotherapy and 5-fluorouracil), which typically produced responses lasting about 10 months. When EXTREME stopped working, options were limited.
That changed with KEYNOTE-048, a global Phase 3 randomized controlled trial published in The Lancet in November 2019. The trial, led by Barbara Burtness at Yale School of Medicine and Kevin Harrington at the Institute of Cancer Research London, enrolled 882 patients with recurrent or metastatic HNSCC who had not received prior systemic treatment for their advanced disease.
Patients were randomly assigned to one of three arms: pembrolizumab (Keytruda) alone; pembrolizumab combined with platinum chemotherapy and 5-fluorouracil; or the standard EXTREME regimen as the control. The key stratifying factor was PD-L1 expression — measured using a Combined Positive Score (CPS) that reflects PD-L1 staining on both tumor cells and immune cells in the tumor microenvironment.
The results reshaped the treatment algorithm for recurrent and metastatic head and neck cancer entirely. In patients with high PD-L1 expression (CPS ≥20, representing about 45% of the trial population), pembrolizumab alone — without any chemotherapy — produced a median overall survival of 14.9 months compared to 10.7 months with EXTREME chemotherapy. The hazard ratio was 0.61, meaning patients receiving pembrolizumab as a single agent had a 39% lower risk of death at any given point.
In the broader PD-L1 positive population (CPS ≥1), pembrolizumab alone extended median overall survival to 13.0 months versus 10.7 months with standard chemotherapy (HR 0.78). Pembrolizumab combined with chemotherapy also outperformed EXTREME in the overall patient population, with median overall survival of 13.6 months versus 10.4 months (HR 0.77).
Critically, pembrolizumab as monotherapy produced this survival benefit with a markedly better side-effect profile. EXTREME is a highly toxic regimen: it requires intravenous infusion every three weeks, frequently causing severe mucositis, kidney toxicity, and profound fatigue. Pembrolizumab, by contrast, is generally well tolerated, allowing patients to maintain a meaningfully better quality of life during treatment.
The FDA approved pembrolizumab as first-line treatment for recurrent or metastatic HNSCC on September 10, 2019, for patients with CPS ≥1 tumors, either alone or in combination with chemotherapy. This was the first new first-line standard of care for this disease in over a decade.
The Vaccine That Can Prevent It
Perhaps the most important public health angle of the HPV-oropharyngeal cancer story is that it is, to a significant degree, preventable — and prevention is already available in every pediatrician’s office and pharmacy in the country.
The HPV vaccine (Gardasil 9, made by Merck) protects against nine HPV strains, including HPV16 and HPV18, which together account for the vast majority of HPV-related cancers. The vaccine was initially approved for girls to prevent cervical cancer. In 2009, it was approved for boys. In 2018, the FDA expanded approval to all adults up to age 45.
But a fundamental gap in public awareness persists: most Americans still think of HPV vaccination as a “girls’ shot” for cervical cancer. In fact, the FDA explicitly approved Gardasil 9 for prevention of oropharyngeal and other head and neck cancers in 2020, based on accumulating evidence that vaccination against HPV16 and HPV18 prevents oral infection with these strains — and therefore prevents the malignant transformation they cause.
Vaccination rates in boys lag significantly behind those in girls. In 2023, CDC data showed that approximately 75% of adolescent girls had received at least one dose of the HPV vaccine, versus approximately 66% of adolescent boys. Given that men are far more likely to develop HPV-positive oropharyngeal cancer, this gap is precisely backwards from a population-health perspective.
The generational protection is beginning to show in the data. Studies from Nordic countries — where national HPV vaccination programs launched earlier and achieved higher coverage — have documented measurable reductions in HPV-related cancers in vaccinated birth cohorts. In the United States, the cohort vaccinated as adolescents beginning in the mid-2000s is now entering the age range where the earliest cancers would be expected to appear, and preliminary surveillance data suggest incidence rates are lower in these vaccinated cohorts. The full preventive effect will take decades to manifest, given HPV’s long latency period, but the mechanism is sound and the early signals are encouraging.
For adults who were not vaccinated as adolescents, the calculus is different. The vaccine is most effective before HPV exposure. For adults who have already been sexually active, the vaccine may not protect against strains already acquired — but it can still provide protection against strains not yet encountered. The FDA-approved age range extends to 45, and discussion with a physician about whether vaccination is appropriate is worthwhile.
Symptoms That Are Easy to Miss
One of the reasons oropharyngeal cancer is so frequently diagnosed at an advanced stage is that its early symptoms are either absent or easily attributed to more common conditions. Unlike oral cavity cancers — where a visible ulcer or white patch in the mouth often prompts evaluation — cancers at the base of the tongue and around the tonsils develop in locations that are not visible in a standard mirror check.
The most common presentation that leads to diagnosis is a painless lump in the neck: an enlarged lymph node that has been colonized by cancer cells that have spread from the primary tumor. By the time a neck node is palpably enlarged, the cancer is typically at Stage III or IV. This sounds alarming, but — given the biology of HPV-positive disease — Stage III and IV HPV-positive oropharyngeal cancers still have survival rates that most other stage IV cancers cannot match.
Other symptoms that should prompt evaluation include:
- Persistent sore throat lasting more than three weeks, particularly if it does not respond to antibiotics and is not associated with other signs of infection
- Difficulty or discomfort swallowing (dysphagia), especially for solid foods, that is new and progressive
- A change in voice quality — hoarseness, muffling, or a “hot potato” quality to the voice
- Ear pain on one side without an obvious ear infection, which can occur because the throat and ear share nerve pathways (referred pain)
- An unexplained neck mass that has been present for more than two to three weeks — this warrants urgent evaluation regardless of other symptoms
Many of these symptoms are also caused by far more common and benign conditions — tonsillitis, allergies, acid reflux. The key indicator that should raise concern is persistence: symptoms that last more than three weeks without a clear cause deserve a physician visit.
What to Do Today
The HPV-oropharyngeal cancer story is unusual in oncology because it spans prevention, early detection, and treatment in ways that are all actionable right now. Several concrete steps are worth knowing:
- If you have children or teenagers, ensure they are vaccinated against HPV. The CDC and the American Cancer Society both recommend HPV vaccination at age 11 or 12 (or as late as 26 for those not previously vaccinated). Gardasil 9 is given as a two-dose series for those vaccinated before age 15, and a three-dose series for older recipients. Vaccination before sexual debut provides near-complete protection against HPV16 and HPV18 — the strains responsible for the vast majority of oropharyngeal cancers.
- If you are a man in your 40s, 50s, or 60s, talk to your doctor about your oropharyngeal cancer risk. There is no routine screening test for this cancer the way there is a Pap smear for cervical cancer. But if you have risk factors — multiple oral sexual partners over your lifetime, or a previous abnormal HPV result — your doctor can ensure symptoms are taken seriously and investigated promptly.
- If you have a persistent neck lump, do not wait. A painless neck mass that has been present for more than three weeks in a middle-aged adult is head and neck cancer until proven otherwise, and should be evaluated urgently with imaging (usually a neck CT or PET scan) and an ENT (ear, nose and throat) specialist or head and neck surgeon.
- If diagnosed with recurrent or metastatic HNSCC, ask about PD-L1 testing. The benefit from pembrolizumab (Keytruda) depends in part on PD-L1 expression measured by the CPS score. This test should be performed on all newly diagnosed recurrent/metastatic cases, and the result guides whether pembrolizumab alone or in combination is the appropriate first-line approach. If your oncology team has not mentioned PD-L1 testing, ask directly.
- Ask about HPV tumor status. At the time of initial diagnosis, all oropharyngeal cancers should be tested for HPV status (p16 immunohistochemistry or HPV ISH). This result has direct implications for prognosis, treatment planning, and eligibility for de-escalation trials. It also provides important psychological context: an HPV-positive diagnosis carries a substantially better expected outcome than an HPV-negative one.
- Seek evaluation at a specialized head and neck cancer center. Management of oropharyngeal cancer requires a multidisciplinary team including a head and neck surgeon, a radiation oncologist experienced in oropharyngeal irradiation, a medical oncologist, and ideally a speech-language pathologist to monitor swallowing function. The differences in outcomes between high-volume centers and lower-volume institutions for this cancer are significant.
The arc of the HPV-oropharyngeal cancer story over the past three decades is, in an odd way, a story of scientific success: a cancer that was mysterious and untreatable twenty years ago is now biologically understood, significantly more survivable, increasingly treatable with immunotherapy rather than toxic chemotherapy, and theoretically preventable through vaccination. The gap between what the science now offers and what most Americans know about this disease remains wide. Closing that gap — one conversation between a patient and a physician, one adolescent vaccinated, one neck lump evaluated promptly — is where the real impact will be measured.